Increased compliance with Optune predicted survival in Novocure’s phase 3 pivotal EF-14 trial in newly diagnosed glioblastoma An Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide versus patients treated with temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today results from …

Third quarter 2017 net revenues of $50.1 million, reflecting 131 percent growth versus third quarter 2016 and 31 percent growth versus second quarter 2017 1,683 active patients at September 30, 2017, an increase of 71 percent from September 30, 2016, and 15 percent from June 30, 2017 Third quarter 2017 cash flow from operations of …

Newly diagnosed glioblastoma patients treated with Optune plus temozolomide were able to maintain quality of life for longer compared to those treated with temozolomide alone Data presented today as a late-breaking oral presentation at the American Society for Radiation Oncology’s 2017 Annual Meeting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today results from its …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it will participate in Noble Capital Markets’ 13th Annual Investor Conference on Jan. 31, 2017, in Boca Raton, Florida. Ashley Cordova, Novocure’s Vice President of Finance and Investor Relations, will speak on behalf of the company and address questions from analysts. Ms. Cordova’s presentation will begin at …

ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune® to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system. Physicians at an additional 291 medical institutions throughout the world also can prescribe Optune to …

1,091 active patients at Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial-stage oncology company developing a proprietary therapy for solid tumors, will provide a business update as well as its preliminary operating statistics for the fourth quarter and full year 2016 at the 35th Annual …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it will report financial results for the fourth quarter and full year 2016 on Thursday, Feb. 23, 2017, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and 12 months ended Dec. …

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune® (NovoTTF-100A) – Novocure’s Tumor Treating Fields (TTFields) delivery system …

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 2 p.m. PST and will …